Syntara Limited · ASX:SNT
Syntara — Investor Presentation (April 2026)
46 slides from Syntara's investor presentation, Apr 29, 2026
Slide 1: Equity Raising Presentation
For personal use only Equity Raising Presentation Gary Phillips, CEO April 2026 Not for release to US wire services or distribution in the United States
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of Syntara Limited ABN 75 082 811 630 (the Company or Syntara) and is dated 29 April 2026. The Company is under no obligation to update or keep the information represented in this presentation current past t
Slide 3: Disclaimer
Disclaimer Geographical restrictions The distribution of this presentation in jurisdictions outside Australia is restricted by law. Please refer to the Foreign jurisdiction selling restrictions section of this presentation. This presentation may not be released For personal use only to US wire servi
Slide 4: Executive Summary
Executive Summary • Syntara is an Australian-founded clinical stage drug developer with lead asset Amsulostat (SNT-5505) a key driver of value with FDA IND and orphan drug designation in myelofibrosis, a disease with a high level of unmet need attracting significant commercial interest. • Amsulostat
Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into 2027 with clinical stage specialist healthcare goal from additional near term data to drive drug developer investors – Phase 2, Phase 1 and value over the next 44% institutional preclinical assets
Slide 6: Syntara Board
SYNTARA BOARD Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experienced senior global • 30+ years’
Slide 7: Experienced Senior Management Team
EXPERIENCED SENIOR MANAGEMENT TEAM Dr Jana Baskar Dr Wolfgang Jarolimek Scientific excellence Chief Medical Officer Head of Drug Discovery • Global leaders in amine oxidase • 20+ years’ experience both in clinical • 25+ years’ experience in pharmaceutical chemistry and biology – key to For personal
Slide 8: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 ini
Slide 9: Amsulostat: Lead Asset and a Key Driver of Value
• FDA IND and orphan drug designation in For personal use only myelofibrosis • First and best in class pan-LOX inhibitor • Long patent life AMSULOSTAT: • Multiple Nature publications LEAD ASSET AND A KEY • Final Phase 2a trial data in combination with DRIVER OF VALUE ruxolitinib presented at ASH 202
Slide 10: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~55k people in 7MM (fibrosis) in bone marrow and abnormal proliferation of (USA, Japan, 5EU); USA ~ 20
Slide 11: Myelofibrosis: Limited Treatment Options Currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat For personal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, inhibiting the family of lysyl oxidase (enlarged
Slide 12: MF-101 Add-on to JAK Inhibitor Ruxolitinib
MF-101 ADD-ON TO JAK INHIBITOR RUXOLITINIB Heterogenous population with a high disease burden STUDY DESIGN PATIENTS TREATED ENDPOINTS For personal use only Phase • 16 2a open label patients study recruited • Multi-national Phase 2a open to evaluate safety, PK/PD, PRIMARY label study to evaluate safe
Slide 13: Total Symptom Score
TOTAL SYMPTOM SCORE Reduction at W24 Additional reduction past W24 73% (8/11) of patients achieved TSS50 at Week 24 or beyond * Pt continued past W38 # Pt completed W52 and study For personal use only Baseline TSS 37 10 52# 32 11* 18# 22# 45# 23# 10# 19# Symptom relief continues 0 for patients: TSS
Slide 14: Spleen Volume Reduction
SPLEEN VOLUME REDUCTION 44% (4/9) of patients achieved SVR25 at Week 24 or beyond For personal use only Improved spleen volume reduction: • At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose • 4/9 (44%) evaluable patients achieved SVR2
Slide 15: Positive Top Line Phase 2a Data Highlights Amsulostat's Potential in Myelofibrosis
POSITIVE TOP LINE PHASE 2A DATA HIGHLIGHTS AMSULOSTAT’S POTENTIAL IN MYELOFIBROSIS For personal use only Improvements of 50% or Meaningful spleen Of the 7 patients Next stage of amsulostat more in total symptom volume reductions that completed 52 clinical and commercial score (TSS50) (SVR) were obse
Slide 16: Competitive Landscape
COMPETITIVE LANDSCAPE Comparable open label Phase 2 studies for drugs under development Latest Phase 2 Open Label Trial Results in Suboptimal Patient Population Drug Program Baseline Characteristics Safety For personal use only Status N TSS50 SVR25 SVR35 (median, range) Grade 3/4 events ≥ 10% Second
Slide 17: Syntara Appoints Global Myelofibrosis Experts
SYNTARA APPOINTS GLOBAL MYELOFIBROSIS EXPERTS TO SUPPORT AMSULOSTAT DEVELOPMENT For personal use only Strategic Advisors to Myelofibrosis Clinical Syntara Board, Haematology Advisory Board • Dr Adam Craig • Professor Claire Harrison Former CEO of CTI BioPharma Corp, responsible Professor of Myelopro
Slide 18: Phase 2b Clinical Trial Design – Subject to FDA Review
PHASE 2b CLINICAL TRIAL DESIGN – SUBJECT TO FDA REVIEW amsulostat Trial Design 200 mg BID Timeline of Activities + For personal use only Main Cohort A Preparation Phase ruxolitinib BID • Patients with MF on ruxolitinib for Main Cohort A • Protocol finalisation n = 50 min 3 months N =75 • CRO selecti
Slide 19: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / For personal use only DATE OF MARCH-2026 DEC-2024 FEB-2024 JUNE-2023 JULY-2022 ANNOUNCEMENT Drug Name Rovadicitinib Elritercept Pelabresib Pacritinib Momelotinib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofib
Slide 20: Indication Expansion: Myelodysplastic Syndrome (MDS)
INDICATION EXPANSION: Myelodysplastic Syndrome (MDS) Market Opportunity ~US$3.2b p.a. High unmet need Diverse bone marrow disorders characterized by inadequate production of healthy blood cells • Therapy for low-risk MDS patients is aimed at For personal use only improving cytopenia(s) to prevent co
Slide 21: Two Studies in MDS to Deliver Phase 1b Data - 2H 2026
TWO STUDIES IN MDS TO DELIVER PHASE 1b DATA - 2H 2026 Generates additional interest from strategics AZALOX: MESSAGE: For personal use only Phase 1b/2a open label study to evaluate safety, PK/PD Phase 1b/2a open label study to evaluate safety, PK/PD and efficacy and efficacy • High risk MDS or interm
Slide 22: Skin Scarring
SKIN SCARRING Leverage expertise in LOX inhibition Standard of Care: Fragmented, Ineffective and Outdated • Silicone sheeting (none to very limited effect) • Skin Scarring is a Global Disease • Steroid injections (temporary; high relapse) For personal use only • Laser therapy (expensive; outcome ope
Slide 23: Clinical Proof of Concept Already Achieved
CLINICAL PROOF OF CONCEPT ALREADY ACHIEVED Placebo controlled study with first generation topical pan LOX inhibitor significantly de risks program SOLARIA2 Findings* For personal use only “We now understand the biology well enough to target stiffness directly rather than just calming inflammation ar
Slide 24: Innovative Trial Design to Evaluate Commercial Viability
INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026 For personal use only Healthy Volunteer Phase 1a Single Ascending Dose Trial design optimised for Dose-dependent target engagement confirmed inclusion criter
Slide 25: Additional Opportunity from Syntara's Pipeline
ADDITIONAL OPPORTUNITY FROM SYNTARA’S PIPELINE Phase 2 placebo controlled study fully funded with non dilutive cash For personal use only • SNT-4728 is a dual SSAO & MAO-B inhibitor, representing a novel anti-inflammatory and neuroprotective approach • Drug extensively de risked from earlier collabo
Slide 26: Fully Recruited Study to Deliver Results Q2 2026
FULLY RECRUITED STUDY TO DELIVER RESULTS Q2 2026 Phase 2 multi-centre, placebo- Study funded by Parkinson’s controlled study assessing effect of UK Virtual Biotech and is For personal use only being run at sites in Sydney, SNT-4728 on microglia activation in Australia and Oxford, UK patients with iR
Slide 27: Equity Raising
For personal use only Equity Raising
Slide 28: Equity Raising Summary
Equity Raising Summary For personal use only • Syntara Limited has received firm commitments for a two tranche non-underwritten placement to raise approximately A$8 million (“Placement”) through the issue of approximately 296.3 million new fully paid ordinary shares (“New Shares”) comprising: o 242,
Slide 29: Use of Funds
Use of Funds Proceeds raised under the $8.0m Placement provides a cash runway to Q3 2027 and will be applied to the following: For personal use only 1. Trial Readouts and Advance MF Licensing Discussions: Targeted Uses of Funds A$m • Fund the Company’s through five key clinical trial read-outs over
Slide 30: Indicative Timetable
Indicative Timetable For personal use only Event Time (AEST) / Date Trading Halt Tuesday, 28 April 2026 SPP Record Date 5:00pm Tuesday, 28 April 2026 Announcement of Placement & SPP, trading halt lifted and recommencement of trade Wednesday, 29 April 2026 Settlement of Tranche 1 Wednesday, 6 May 202
Slide 31: For personal use only
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au
Slide 32: Risks
Risks The Company’s business is subject to a number of significant risks and uncertainties both specific to its business and of a general nature, some of which are summarised below. For personal use only As such, potential investors should be aware that investing in the Company’s securities involves
Slide 33: Key business risks
Key business risks (a) Overview The Company’ business success is currently substantially dependent on its ability to successfully advance the clinical development of amsulostat (SNT-5505), SNT- For personal use only 9465, SNT-6302 (and related back up compounds) and SNT-4728 in a timely manner. Ther
Slide 34: Key business risks
Key business risks (c) The time and cost to undertake clinical trials and obtain regulatory approval may be significantly more than expected The length of time and the cost necessary to complete clinical trials and to submit an application for marketing approval may vary significantly based on the t
Slide 35: Key business risks
Key business risks (e) The Company may not be successful in developing or securing new product candidates Although the Company already has an extensive product candidate pipeline, it continues to spend limited resources developing new product candidates. From For personal use only time to time it al
Slide 36: Key business risks
Key business risks h) Mannitol business unit In October 2023 the Company sold its mannitol business unit. Notwithstanding the sale, the Company has certain residual risks associated with the mannitol business unit. The Company maintains the risks for liabilities arising from the operation of the man
Slide 37: Key business risks
Key business risks (k) Even if a product is approved, the product may not warrant launch or even if launched, may not be successful in the market There is a risk that the product candidates the Company is developing and future product candidates, even if they receive regulatory approval may not gain
Slide 38: Key business risks
Key business risks (p) Patents and trade secrets The Company uses patents or trade secrets to protect its technologies from unauthorised use by third parties. The term of patents may expire or may be For personal use only challenged, invalidated or circumvented. There can be no assurances that the C
Slide 39: Foreign jurisdiction selling restrictions
Foreign jurisdiction selling restrictions This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold,
Slide 40: Foreign jurisdiction selling restrictions
Foreign jurisdiction selling restrictions Singapore This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in For personal use only Singapore with the Monetary Authority of Singapore. Accordingly, this document and any ot
Slide 41: Foreign jurisdiction selling restrictions
Foreign jurisdiction selling restrictions United States For personal use only This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or th
Slide 42: Appendix
For personal use only APPENDIX
Slide 43: Lysyl Oxidases in Myelofibrosis
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Lysyl oxidase (LOX) gene family upregulated in the bone marrow (BM) of myelofibrosis patients For personal use only → Increased LOX activity adversely impacts BM health in several ways* Structural Effects
Slide 44: Lysyl Oxidases in Myelofibrosis
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Amsulostat inhibits lysyl oxidase (LOX) activity and has a multi-faceted mode of action For personal use only Amsulostat Inhibits cross-link formation Reduces mechanical stress Inhibits signalling of a
Slide 45: MF-201 Proposed Study Design – Subject to FDA Review
MF-201 PROPOSED STUDY DESIGN –SUBJECT TO FDA REVIEW Study Population – Main Cohort A Primary Endpoint • Patients with MF (PMF or Post-ET/PV MF) • TSS50 as measured by MFSAF v4.0 at For personal use only • On ruxolitinib* for min 3 months (Stable 8 Week 36 wks) • Current inadequate response to Second
Slide 46: Lysyl Oxidases and MDS
LYSYL OXIDASES AND MDS HYPOTHESIS: Lysyl oxidase activity is increased Correction of elevated lysyl oxidase Impressive preclinical results in bone marrow aspirates from activity in bone marrow published in Nature For personal use only MDS patients. microenvironment could be of • Amsulostat on top of